Choroidal neovascularisation (pathological myopia) - ranibizumab: evaluation report

01. Pre-meeting Briefing prepared by NICE

02. Final Scope

03. Final Matrix

04. Submission from the technology manufacturer – Novartis

05. NICE request to Manufacturer for clarification on their submission

06. Manufacturer clarification response

07. Consultee submission – Macular Society

08. Consultee submission – Royal National Institute of Blind People

09. Consultee submission – Royal College of Ophthalmologists

10. Consultee submission Royal College of Pathologists

11. Clinical expert perspective – Bailey 

12. Patient expert personal perspective – Eaglen

13. Clinical expert perspective – Sivaprasad

14. Evidence Review Group Report prepared by Aberdeen HTA Group

15. Manufacturer factual accuracy check of Evidence Review Group report

16. Evidence Review Group – Erratum

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *

This page was last updated: 18 October 2013